243 related articles for article (PubMed ID: 28628466)
41. The Clinical Relevance of Antifibrillarin (anti-U3-RNP) Autoantibodies in Systemic Sclerosis.
Tall F; Dechomet M; Riviere S; Cottin V; Ballot E; Tiev KP; Montin R; Morin C; Chantran Y; Grange C; Jullien D; Ninet J; Chretien P; Cabane J; Fabien N; Johanet C
Scand J Immunol; 2017 Jan; 85(1):73-79. PubMed ID: 27864990
[TBL] [Abstract][Full Text] [Related]
42. Distinct Scleroderma Autoantibody Profiles Stratify Patients for Cancer Risk at Scleroderma Onset and During the Disease Course.
Kim JS; Woods A; Gutierrez-Alamillo L; Laffoon M; Wigley FM; Hummers LK; Rosen A; Zeger S; Domsic RT; Casciola-Rosen L; Shah AA
Arthritis Rheumatol; 2024 Jan; 76(1):68-77. PubMed ID: 37488962
[TBL] [Abstract][Full Text] [Related]
43. To what extent do autoantibodies help to identify high-risk patients in systemic sclerosis?
Boonstra M; Mertens BJA; Bakker JA; Ninaber MK; Ajmone Marsan N; van der Helm-van Mil AHM; Scherer HU; Huizinga TWJ; de Vries-Bouwstra JK
Clin Exp Rheumatol; 2018; 36 Suppl 113(4):109-117. PubMed ID: 30148428
[TBL] [Abstract][Full Text] [Related]
44. Clinical and laboratory aspects of Ro/SSA-52 autoantibodies.
Defendenti C; Atzeni F; Spina MF; Grosso S; Cereda A; Guercilena G; Bollani S; Saibeni S; Puttini PS
Autoimmun Rev; 2011 Jan; 10(3):150-4. PubMed ID: 20854935
[TBL] [Abstract][Full Text] [Related]
45. A case of anti-RuvBL1/2 antibody-positive systemic sclerosis overlapping with myositis.
Nomura Y; Ueda-Hayakawa I; Yamazaki F; Ozaki Y; Hamaguchi Y; Takehara K; Okamoto H
Eur J Dermatol; 2020 Feb; 30(1):52-53. PubMed ID: 32031537
[No Abstract] [Full Text] [Related]
46. Protective Effect Against Cancer of Antibodies to the Large Subunits of Both RNA Polymerases I and III in Scleroderma.
Shah AA; Laiho M; Rosen A; Casciola-Rosen L
Arthritis Rheumatol; 2019 Sep; 71(9):1571-1579. PubMed ID: 30888702
[TBL] [Abstract][Full Text] [Related]
47. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody.
Allenbach Y; Keraen J; Bouvier AM; Jooste V; Champtiaux N; Hervier B; Schoindre Y; Rigolet A; Gilardin L; Musset L; Charuel JL; Boyer O; Jouen F; Drouot L; Martinet J; Stojkovic T; Eymard B; Laforêt P; Behin A; Salort-Campana E; Fain O; Meyer A; Schleinitz N; Mariampillai K; Grados A; Benveniste O
Brain; 2016 Aug; 139(Pt 8):2131-5. PubMed ID: 27086869
[TBL] [Abstract][Full Text] [Related]
48. [Anti-Scl-70 and anti-centromere autoantibodies. Biological markers of 2 forms of systemic scleroderma].
Johanet C; Agostini MM; Vayssairat M; Abuaf N
Presse Med; 1989 Feb; 18(5):207-11. PubMed ID: 2522207
[TBL] [Abstract][Full Text] [Related]
49. Four Cases of Anti-PM/Scl Antibody-positive Juvenile Overlap Syndrome with Features of Myositis and Systemic Sclerosis.
Fotis L; Baszis KW; White AJ; French AR
J Rheumatol; 2016 Sep; 43(9):1768-9. PubMed ID: 27587018
[No Abstract] [Full Text] [Related]
50. Rare myositis-specific autoantibody associations among Hungarian patients with idiopathic inflammatory myopathy.
Bodoki L; Nagy-Vincze M; Griger Z; Betteridge Z; Szöllősi L; Jobanputra R; Dankó K
Acta Reumatol Port; 2015; 40(4):337-47. PubMed ID: 26922197
[TBL] [Abstract][Full Text] [Related]
51. Antibodies to defined antigens in the systemic rheumatic diseases.
Reichlin M
Bull Rheum Dis; 1993 Dec; 42(8):4-6. PubMed ID: 8173650
[TBL] [Abstract][Full Text] [Related]
52. Interpretation of an Extended Autoantibody Profile in a Well-Characterized Australian Systemic Sclerosis (Scleroderma) Cohort Using Principal Components Analysis.
Patterson KA; Roberts-Thomson PJ; Lester S; Tan JA; Hakendorf P; Rischmueller M; Zochling J; Sahhar J; Nash P; Roddy J; Hill C; Nikpour M; Stevens W; Proudman SM; Walker JG
Arthritis Rheumatol; 2015 Dec; 67(12):3234-44. PubMed ID: 26246178
[TBL] [Abstract][Full Text] [Related]
53. Human scleroderma sera contain autoantibodies to protein components specific to the U3 small nucleolar RNP complex.
Yang JM; Hildebrandt B; Luderschmidt C; Pollard KM
Arthritis Rheum; 2003 Jan; 48(1):210-7. PubMed ID: 12528121
[TBL] [Abstract][Full Text] [Related]
54. Autoantibodies to RNA-polymerases in Italian patients with systemic sclerosis.
Bardoni A; Rossi P; Salvini R; Bobbio-Pallavicini F; Caporali R; Montecucco C
Clin Exp Rheumatol; 2003; 21(3):301-6. PubMed ID: 12846047
[TBL] [Abstract][Full Text] [Related]
55. Systematic autoantigen analysis identifies a distinct subtype of scleroderma with coincident cancer.
Xu GJ; Shah AA; Li MZ; Xu Q; Rosen A; Casciola-Rosen L; Elledge SJ
Proc Natl Acad Sci U S A; 2016 Nov; 113(47):E7526-E7534. PubMed ID: 27821747
[TBL] [Abstract][Full Text] [Related]
56. Autoantibodies in systemic sclerosis.
Steen VD
Semin Arthritis Rheum; 2005 Aug; 35(1):35-42. PubMed ID: 16084222
[TBL] [Abstract][Full Text] [Related]
57. South Australian Scleroderma Register: autoantibodies as predictive biomarkers of phenotype and outcome.
Graf SW; Hakendorf P; Lester S; Patterson K; Walker JG; Smith MD; Ahern MJ; Roberts-Thomson PJ
Int J Rheum Dis; 2012 Feb; 15(1):102-9. PubMed ID: 22324953
[TBL] [Abstract][Full Text] [Related]
58. Low prevalence of anti-RNA polymerase III antibodies in a French scleroderma population: anti-RNA polymerase III scleroderma.
Faucher B; Stein P; Granel B; Weiller PJ; Disdier P; Serratrice J; Harlé JR; Durand JM; Frances Y; Guis S; Pham T; Bardin N; Sanmarco M
Eur J Intern Med; 2010 Apr; 21(2):114-7. PubMed ID: 20206882
[TBL] [Abstract][Full Text] [Related]
59. C1D is a major autoantibody target in patients with the polymyositis-scleroderma overlap syndrome.
Schilders G; Egberts WV; Raijmakers R; Pruijn GJ
Arthritis Rheum; 2007 Jul; 56(7):2449-54. PubMed ID: 17599775
[TBL] [Abstract][Full Text] [Related]
60. Function blocking autoantibodies against matrix metalloproteinase-1 in patients with systemic sclerosis.
Sato S; Hayakawa I; Hasegawa M; Fujimoto M; Takehara K
J Invest Dermatol; 2003 Apr; 120(4):542-7. PubMed ID: 12648215
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
